Express Scripts Anticipates Growth In 2005 From Zithromax, Zofran Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
PBM cites anticipated contribution to growth from several first-time generics that could enter the market in 2005. Nevertheless, Express Scripts concedes that generic utilization growth will be weaker in 2005 than in other years. Subsidiary CuraScript will aid PBM's growth by converting clients that use an outside specialty pharmacy provider.
You may also be interested in...
PBMs Eye Acquisitions In “Target-Rich Environment”
Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.
PBMs Eye Acquisitions In “Target-Rich Environment”
Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.
Generic Drug Price War Could Pay Off For PBMs
Pharmacy benefit managers earn higher profits on generics over brand products, Express Scripts CEO Toan says, and lower prices will lead to increased generic utilization. Caremark has gotten “some pickup” from the pricing competition, CEO Crawford says.